Mycophenolate Mofetil as an Effective Corticosteroid-Sparing Therapy for Recalcitrant Dermatomyositis
Johnathon C. Edge, MD;
J. David Outland, MD;
Jennifer R. Dempsey, MD;
Jeffrey P. Callen, MD
Arch Dermatol. 2006;142:65-69.
Background Dermatomyositis (DM) is a multisystem idiopathic inflammatory disorder that most commonly affects the muscles and skin. Systemic corticosteroids are the mainstay of therapy but are limited by their long-term adverse effects.
Observations We sought to evaluate the effectiveness of oral mycophenolate mofetil in patients with cutaneous lesions of DM recalcitrant to other therapies through an open-label retrospective medical chart review of patients in a university-affiliated private practice setting. Twelve patients with DM who had skin lesions recalcitrant to traditional therapies or who developed toxic effects from traditional therapies began mycophenolate mofetil treatment at doses ranging from 500 mg to 1 g twice a day. Response was based on improvement in skin disease as judged clinically, an increase in strength, and/or an ability to decrease or discontinue concomitant therapies. Improvement was seen in 10 of the 12 patients, most within 4 to 8 weeks. Most patients tolerated mycophenolate mofetil treatment without problem; however, 1 patient developed a B-cell lymphoma of the central nervous system, and another developed abnormal levels of hepatic enzymes along with urinary symptoms. Resolution of these toxic reactions occurred with cessation of mycophenolate mofetil treatment in each patient.
Conclusion Mycophenolate mofetil may be an effective corticosteroid-sparing therapy for the treatment of some patients with DM.
Author Affiliations: Division of Dermatology, Department of Medicine, University of Louisville School of Medicine, Louisville, Ky.
RELATED ARTICLES
Liver Enzyme Abnormalities in Patients With Atopic Dermatitis Treated With Mycophenolate Mofetil
Basil Hantash and David Fiorentino
Arch Dermatol. 2006;142(1):109-110.
EXTRACT
| FULL TEXT
An Unusual Presentation of Amyopathic Dermatomyositis Associated With Fatal Interstitial Lung Disease
Isaac M. Neuhaus and M. Kari Connolly
Arch Dermatol. 2006;142(1):113-114.
EXTRACT
| FULL TEXT
Improvement in Dermatomyositis Rash Associated With the Use of Antiestrogen Medication
Danya Sereda and Victoria P. Werth
Arch Dermatol. 2006;142(1):70-72.
ABSTRACT
| FULL TEXT
The Era of Cooperation
Michael P. Heffernan
Arch Dermatol. 2006;142(1):93-95.
EXTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Mycophenolate mofetil: an overview
Sinclair and Baildon
Lupus 2006;15:70-77.
Prevention of Osteoporosis Associated With Chronic Glucocorticoid Therapy
Heffernan et al.
JAMA 2006;295:1300-1303.
FULL TEXT
The Era of Cooperation
Heffernan
Arch Dermatol 2006;142:93-95.
FULL TEXT
|
